These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28334974)

  • 1. Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial.
    Oyama M; Sugiyama T; Nozawa M; Fujimoto K; Kishida T; Kimura G; Tokuda N; Hinotsu S; Shimozuma K; Akaza H; Ozono S
    Jpn J Clin Oncol; 2017 Jun; 47(6):551-559. PubMed ID: 28334974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
    Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
    Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
    Guo J; Huang Y; Zhang X; Zhou F; Sun Y; Qin S; Ye Z; Wang H; Jappe A; Straub P; Pirotta N; Gogov S
    BMC Cancer; 2013 Mar; 13():136. PubMed ID: 23514360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial.
    Staehler M; Stöckle M; Christoph DC; Stenzl A; Potthoff K; Grimm MO; Klein D; Harde J; Brüning F; Goebell PJ; Augustin M; Roos F; Benz-Rüd I; Marschner N; Grünwald V
    Int J Cancer; 2021 Apr; 148(7):1685-1694. PubMed ID: 33070307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study.
    Bergmann L; Goebell PJ; Kube U; Kindler M; Herrmann E; Janssen J; Schmitz J; Weikert S; Steiner G; Jakob A; Staehler MD; Steiner T; Overkamp F; Albrecht M; Guderian G; Doehn C
    Onkologie; 2013; 36(3):95-100. PubMed ID: 23485996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
    Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
    Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
    Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
    Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.
    Davis ID; Long A; Yip S; Espinoza D; Thompson JF; Kichenadasse G; Harrison M; Lowenthal RM; Pavlakis N; Azad A; Kannourakis G; Steer C; Goldstein D; Shapiro J; Harvie R; Jovanovic L; Hudson AL; Nelson CC; Stockler MR; Martin A
    Ann Oncol; 2015 Jun; 26(6):1118-1123. PubMed ID: 25701452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
    Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
    Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
    Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
    Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
    Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I;
    Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experience with everolimus therapy for patients with metastatic renal cancer in Hungary].
    Maráz A; Bodoky G; Dank M; Géczi L; Kahán Z; Mangel L; Révész J; Szűcs M
    Magy Onkol; 2014 Mar; 58(1):4-9. PubMed ID: 24712001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
    Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
    Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
    Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
    Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis.
    Yang L; Alyasova A; Ye D; Ridolfi A; Dezzani L; Motzer RJ
    BMC Cancer; 2018 Feb; 18(1):195. PubMed ID: 29454306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI.
    Park K; Lee JL; Park I; Park S; Ahn Y; Ahn JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Med Oncol; 2012 Dec; 29(5):3291-7. PubMed ID: 22460837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis.
    Bracarda S; Hutson TE; Porta C; Figlin RA; Calvo E; Grünwald V; Ravaud A; Motzer R; Kim D; Anak O; Panneerselvam A; Escudier B
    Br J Cancer; 2012 Apr; 106(9):1475-80. PubMed ID: 22441644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT).
    Sheng X; Ye D; Zhou A; Yao X; Luo H; He Z; Wang Z; Zhao Y; Ji Z; Zou Q; He C; Guo J; Tu X; Liu Z; Shi B; Liu B; Chen P; Wei Q; Hu Z; Zhang Y; Jiang K; Zhou F; Wu D; Fu C; Li X; Wu B; Wang L; Qin S; Li G; Liu Y; Guo H; Chen K; Zhang D; Wang G; Ding L; Wang Y; Yuan X; Guo J
    Eur J Cancer; 2023 Jan; 178():205-215. PubMed ID: 36459768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.
    Oudard S; Joly F; Geoffrois L; Laguerre B; Houede N; Barthelemy P; Gross-Goupil M; Vano Y; Lucidarme O; Bidault F; Kelkouli N; Slimane K; Escudier B
    Clin Genitourin Cancer; 2016 Dec; 14(6):e595-e607. PubMed ID: 27283478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies.
    Albiges L; Kube U; Eymard JC; Schmidinger M; Bamias A; Kelkouli N; Mraz B; Florini S; Guderian G; Cattaneo A; Bergmann L
    Eur J Cancer; 2015 Nov; 51(16):2368-74. PubMed ID: 26276039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.